Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference
Johnson & Johnson (NYSE:JNJ ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ET Corporate Participants Joe Wolk - EVP, Chief Financial Officer Conference Call Participants Shagun Singh - RBC Capital Markets Shagun Singh Hello everyone, I am Shagun Singh, Senior Research Analyst at RBC, and I'm very happy to host the next session with Johnson & Johnson. Joining us from the company is Joe Wolk, Chief Financial Officer of the company.
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
If You Invested $25,000 In Johnson & Johnson (JNJ) 20 Years Ago, This Is How Much Cash From Dividends You Would Have Today
Companies with strong products, good management, solid earnings and growth trends, and a history of annual dividend increases are often popular buy and hold stocks to take advantage of dividend compounding.
Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ ) BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ET Company Participants John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Tim Anderson - Bank of America Tim Anderson I think we're live. Thank you for joining us.
Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the specific breakdown of the trade between these two countries and JNJ's relatively minor exposure to China.
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?
Both JNJ and ABBV expect their sales and profits to improve in 2025.
2 Bulletproof Dividend Stocks to Buy in May
Dividend stock investing has long been a cornerstone for building wealth, offering investors a steady stream of passive income while providing a buffer against market volatility.
J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports
HistoSonics, a medical technology company backed by Johnson & Johnson , is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing people familiar with the matter.
3 Industry Behemoths Are Rewarding Investors With Dividend Bumps
In a market where investors are increasingly seeking stability and reliable returns, several industry giants have stepped up with significant dividend increases. Johnson & Johnson NYSE: JNJ, Costco Wholesale NASDAQ: COST, and NASDAQ NASDAQ: NDAQ have each announced meaningful hikes to their quarterly payouts, reinforcing their commitment to shareholder value even amid broader market volatility.
